The prognostic marker NRIP1 is associated with tumor progression and immune infiltration in acute myeloid leukemia
Year: 2025
Type: article
Abstract: Acute myeloid leukemia (AML) is a clinically aggressive hematologic malignancy characterized by high relapse rates and treatment resistance, highlighting the need for novel biomarkers to improve clinical outcomes. This study explores the roles of nuclear receptor-interacting protein 1 (NRIP1) in AML, focusing on its associations with tumor progression and immune infiltration. Analysis of public AML gene expression datasets reveals that NRIP1 expression is significantly increased in AML patients. High NRIP1 expression is associated with significantly shorter survival rates than low NRIP1 expression is. Furthermore, NRIP1 expression is significantly associated with the infiltration of diverse immune cells, including B cells, dendritic cells, T cells, mast cells, eosinophils, and T helper cells, suggesting its potential role in modulating the immune microenvironment to influence AML progression. Functional enrichment analysis indicates that NRIP1 and its interacting partners are involved in tumorigenesis, immune microenvironment remodelling, and metabolic reprogramming. Survival analysis confirms the prognostic value of NRIP1. Furthermore, functional validation in AML cell lines confirms that NRIP1 knockdown suppresses proliferation and induces apoptosis, underscoring its oncogenic role. Our study identifies NRIP1 as a multifaceted regulator associated with poor prognosis, immune infiltration, and ferroptosis in AML, identifying NRIP1 as a novel potential prognostic biomarker.
DOI: 10.3724/abbs.2025197
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4415208938